NPS Pharmaceuticals (NPSP) Gets FDA Committee Meeting Date for Gattex NDS; PDUFA in December

Article Stock Quotes (1) Comments (0)

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP), announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex® (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012. The Prescription Drug User Fee Act (PDUFA) date for completion of review by the FDA is December 30, 2012.

Gattex is a novel, recombinant analog of human glucagon-like peptide 2, a peptide involved in normal intestinal function and fluid and nutrient absorption. The proposed indication for Gattex is the treatment of adult patients with short bowel syndrome.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero Over Rapaflo Patent
• GlaxoSmithKline (GSK) Receives Bid for Thrombosis Brands, NDB Site
• Initial Findings from PARADOX, Largest and Most Comprehensive Research Analyzing the Burden of Hypoparathyroidism, Reveals Collection of Nearly 40 Physical, Cognitive, Emotional Symptoms

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?